The QualityStocks Daily Newsletter for Monday, July 26th, 2010 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters


Stock Source (FLTWQ)


Stock Traders Chat (TITL)


Xplosive Stocks (INAR)

The QualityStocks Daily

Alveron Energy Corp‏. (AECP)

Today we are highlighting Alveron Energy Corp‏. (AECP) as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Alveron Energy Corp. is a development stage company that trades on the OTC Bulletin Board. The Company incorporated under the laws of the State of Delaware on November 18, 2003. They are a development stage wind and hydroelectric energy generation enterprise. Alveron Energy Corp‏. has their corporate headquarters in Toronto, Ontario.

From their beginning to September 2007, the Company was focused on providing a vehicle for a foreign or domestic non-public company to become an SEC reporting publicly traded company. However, the Company shifted their focus to becoming the aforementioned wind and hydroelectric energy generation company.

Earlier this year, the Company formed a new Joint Venture Corporation (JVC) as per the agreement signed on June 20, 2009. This JVC, “Yantai Alveron Energy Development Company”, is 77 percent owned by Alveron Energy with the remaining 23 percent owned by joint partners. Alveron Energy Corp. transferred $50,000 to this new entity during the quarter ending April 30, 2010. These funds are to be used on the feasibility report for a potential 48MW wind energy plant in Shandong, China.

Alveron Energy Corp‏. has begun preliminary investigation into wind and hydro energy technologies and has been researching wind and hydroelectric energy properties and project opportunities. The Company is also developing their economic models and financial forecasts while raising capital. They are working to identify regions that are economically viable for wind or hydro turbine development and development partners that would be appropriate for a particular project.

The Company is also engaging in data collection. For the wind energy projects, this involves location mapping and wind resource data monitoring and collection. This is through using meteorological instruments, especially anemometers, which read wind-speed and direction among other things. For hydroelectric projects, this involves location mapping and water resource data monitoring and collection. This is through using acoustical current instruments, as well as recorded and ongoing data collected by publicly accessible stations.

We're keeping an eye on Alveron Energy Corp‏. (AECP) and tracking them on our radar screens as "One to Watch", here at the QualityStocks Daily Newsletter.

Alveron Energy Corp‏. (AECP) closed Monday's session at no price on no trading activity as of yet.

Seattle Genetics Inc. (SGEN)

Greenbackers, Penny Sleuth, Trading Markets, and Today's Financial News reported earlier on Seattle Genetics Inc. (SGEN), and we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Seattle Genetics is a clinical stage biotechnology company. They focus on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. One of the cornerstones of the Company's business strategy is collaborating with leading biopharmaceutical companies. Trading on the NASDAQ Global Market, Seattle Genetics Inc. has their headquarters in Bothell, Washington.

The Company's lead product candidate is brentuximab vedotin. This is in a pivotal trial under a Special Protocol Assessment with the U.S. Food and Drug Administration. Brentuximab vedotin is undergoing development in collaboration with Millennium: The Takeda Oncology Company.

Seattle Genetics also has five other clinical-stage programs. These are lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70, SGN-75, and ASG-5ME. The Company has collaborations for their ADC technology with a number of prominent biotechnology and pharmaceutical companies.

These include Bayer, Celldex Therapeutics, Daiichi Sankyo, and Genentech. They also include GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as an ADC co-development agreement with Agensys, an affiliate of Astellas.

The Company's proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell. Consequently, this spares normal tissue the toxicity of traditional chemotherapy.

On July 20, 2010, Seattle Genetics, Inc. and Agensys, Inc. announced that they initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. Agensys, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc.

The single-agent, phase I, open-label, dose-escalation study will evaluate the safety and tolerability of ASG-5ME in patients with pancreatic cancer and identify the maximum tolerated dose. Secondary objectives include assessing the pharmacokinetics and antitumor activity of ASG-5ME. They also include identifying a recommended dose and regimen for future clinical trials. The design of the study is to enroll up to approximately 50 patients at multiple centers in the U.S.
Seattle Genetics Inc. (SGEN) closed today's trading session at $13.00, up 4.17%, on 366,858 volume.

Interval Leisure Group, Inc. (IILG)

We are highlighting Interval Leisure Group, Inc. (IILG), here at the QualityStocks Daily Newsletter.

Trading on the NASDAQ Global Select Market, Interval Leisure Group, Inc. is a leading global provider of membership and leisure services to the vacation industry. The Company's principal business segment, Interval International, has been serving the vacation ownership market for more than 33 years. Interval International is a membership-based organization. Interval International operates membership programs for vacation owners and provides value-added services to their developer clients worldwide. Interval Leisure Group, Inc. has their headquarters in Miami, Florida.

Interval International offers a comprehensive package of year-round benefits, including the opportunity to exchange the use of shared ownership vacation time for alternate accommodations. Interval has a network of approximately 2,500 resorts in more than 75 countries. The Company offers their resort clients and approximately 2 million member families' high-quality products and programs through offices in 14 countries.

Interval Leisure Group's other business segment is Aston, formerly ResortQuest Hawaii. It has a lodging history of almost 60 years. Aston Hotels & Resorts and Maui Condo and Home provide hotel and resort management and vacation rental services through a portfolio of approximately 5,000 units. This is to vacationers and property owners primarily in the Hawaiian Islands.

On July 8, 2010, Interval International announced that they added Bali Palms Resort to their exchange network. In the East Bali town of Candi Dasa, the fractional vacation residences include studios and one- and two-bedroom apartments available in 3, 6 or 9-month increments. The property offers panoramic views of the ocean, dotted with small islands, as well as the surrounding mountains. This includes Bali’s highest and most sacred Mount Agung.

On July 15, 2010, Interval International announced the addition of Grand Miramar Club & Spa to their exchange network. The luxury resort is in the Sierra Madre Mountains in Conchas Chinas. This is a neighborhood known as the "Beverly Hills of Puerto Vallarta, Mexico." Grand Miramar Club & Spa will include 103 spacious one- to four-bedrooms units with scenic views of the Banderas Bay, upon completion. The first 38 units are available and the remaining 65 are scheduled to open mid-year 2011.

Today, Interval Leisure Group, Inc. (IILG) closed at $13.94, up 7.15%, on 156,388 volume.

Dynegy Inc. (DYN)

StreetAlerts reported earlier on Dynegy Inc. (DYN), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Founded in 1984, Dynegy Inc., via their subsidiaries, produces and sells electric energy, capacity and ancillary services in key U.S. markets. The power generation portfolio consists of approximately 12,500 megawatts of baseload, intermediate and peaking power plants fueled by a mix of natural gas, coal and fuel oil. Dynegy Inc. trades on the New York Stock Exchange (NYSE). The Company has their corporate headquarters in Houston, Texas. They have 1,800 employees nationwide.

The Company began in 1984 as Natural Gas Clearinghouse, a marketer of natural gas. In 1997, they acquired Destec Energy Inc. This marked Dynegy's entrance into the independent power producer sector. In 1998, they changed their name from Natural Gas Clearinghouse to Dynegy Inc.

The Company provides wholesale power, capacity and ancillary services to utilities, cooperatives, municipalities and other energy companies. They provide all of this in seven states in their key U.S. regions of the Midwest, the Northeast and the West Coast. Dynegy Inc.'s geographic, dispatch and fuel diversity contribute to a portfolio well positioned to capitalize on regional differences in power prices and weather-driven demand.

In the Midwest, the Company has approximately 5,600 megawatts of generation capacity. In the West, they have approximately 4,100 megawatts of generation capacity. In the Northeast, they have approximately 3,300 megawatts of generation capacity.

Dynegy Inc.'s customers include regional transmission organizations, independent system operators, integrated utilities, municipalities, electric cooperatives, and transmission and distribution utilities. They also include industrial customers, power marketers, other power generators, commercial end-users, and financial participants, such as banks and hedge funds.

On July 6, 2010, Dynegy Inc. announced that they plan to report second quarter 2010 financial results before the opening of the New York Stock Exchange on Friday, August 6, 2010. In connection with the announcement, Dynegy Chairman, President and Chief Executive Officer, Bruce A. Williamson, and members of the Company’s senior management team will discuss results during an investor presentation to be webcast live beginning at 10 a.m. ET/9 a.m. CT on August 6.

Dynegy Inc. (DYN) closed Monday's session at $3.74, up 1.08%, on 2,039,799 volume with 7,311 trades. The stock’s average daily volume over the past 60 days is 6,320,092 with a 52-week low/high of $3.46/$13.35.

Weikang Bio-Technology Group Co., Inc. (WKBT)

Wall Street News Alert and Investor Alerts reported earlier on Weikang Bio-Technology Group Co., Inc. (WKBT), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Weikang Bio-Technology Group Co., Inc. is a Chinese producer of Over-the-Counter (OTC) pharmaceuticals and traditional Chinese medicine (TCM) products. Trading on NASDAQ's OTCBB, the Company has their headquarters in Harbin, China. In addition, they have two production facilities.

Weikang Bio-Technology Company, Inc. received incorporation in Florida on May 12, 2004 as Expedition Leasing, Inc. On December 7, 2007, the Company acquired Sinary Bio-Technology Holdings Group, Inc. and Sinary's wholly owned subsidiary Heilongjiang Weikang Bio-Technology Group Co., Ltd., a limited liability company in China.

Sinary, with no substantive operations that they conduct, through Heilongjiang Weikang engages in the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine (TCM) in China. All of the Company's products are Chinese herbal-based health and nutritional supplements. They actively look to maintain and improve the quality of their products, and as of April 2006, they have implemented the "GB/T19001-2000 idt ISO9001:2000" quality-assurance management system to all of their manufacturing processes.

Heilongjiang Weikang is located in Heilongjiang Province in Northeastern China. Their principal office and manufacturing facility is in the Economic and Technology Development Zone in the city of Shuangcheng, approximately 42 kilometers south of the provincial capital Harbin.

Through Heilongjiang Weikang, they manufacture and distribute in China a series of internally developed health supplements under a Chinese trade name. Its English transliteration is "Rongrun". The "Rongrun" line currently includes seven products. They also developed two new products during 2007, which received approval from the Heilongjiang Department of Health.

On July 22, 2008, Heilongjiang Weikang acquired 100 percent of the issued and outstanding equity interest of Tianfang (Guizhou) Pharmaceutical Co., Ltd. They are a Chinese limited liability company. Tianfang received incorporation in Guizhou Province, China in 1998. Tianfang engages in the development, manufacture, and distribution of OTC Pharmaceuticals. Through their acquisition of Tianfang, Weikang Bio-Technology Group Co., Inc. is expanding their business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals.

Last month, Weikang Bio-Technology Group announced that they are launching a new project. This is to research and develop licorice flavonoids for use in therapeutics. Licorice contains glycyrrhetinic acid. It is widely used as a flavoring agent. It has also been shown to be effective in treating conditions and afflictions such allergies, hepatitis, inflammation and swelling. This includes peptic ulcers, hypertension, and excessive potassium in the body, skin conditions, viral infections, tumor formation and weight loss. The Company anticipates sales of therapeutics derived from the project will add approximately $13 million to annual revenue and approximately $5.7 million in annual after-tax net income.

Weikang Bio-Technology Group Co., Inc. (WKBT) closed Monday at $3.18, up 11.98%, on 8,989 volume with 20 trades. The stock’s average daily volume over the past 60 days is 2,890 with a 52-week low/high of $0.25/$6.99

EnergyConnect Group, Inc. (ECNG)

We are highlighting EnergyConnect Group, Inc. (ECNG) today, here at the QualityStocks Daily Newsletter.

EnergyConnect Group, Inc. is a leading provider of smart grid demand response services and technologies. Demand response programs provide grid operators with additional electricity generation capacity by encouraging consumers to curtail their electricity usage.  

EnergyConnect Group, Inc. delivers Demand Response solutions to commercial, educational, and industrial consumers. This enables their customers to manage their electricity use in response to market prices (Economic), regional power shortages (Capacity), or cost avoidance measures. Founded in 1998, EnergyConnect Group, Inc. has their headquarters in Campbell, California. They trade on the OTC Bulletin Board.

The EnergyConnect platform provides a scalable, cost-effective, clean technology to enhance the grid's efficiency and reliability. The majority of facilities already have the potential to realize economic benefit from the energy used in their facilities every day. Using the Company's tools and services, organizations experience substantial cost savings and cash incentives while ensuring a greener future.

The Company allows commercial and industrial consumers of electricity to access demand response programs offered by the grid and get paid by agreeing to stand by and curtail based upon a grid event or responding to a price signal. EnergyConnect Group allows this via their proprietary software as a service (SaaS) platform.

Their customers are commercial and industrial consumers of electricity that they contract with to identify, develop, and if necessary implement curtailment strategies. The Company enrolls their customers in demand response programs operated by grid operators, who pay EnergyConnect Group, Inc. for standing by or by reducing load by responding to a price signal. The Company then passes on a portion of these payments to their customers in accordance with their contract with them.

On July 21, 2010, EnergyConnect Group, Inc. announced that they intend to release their second quarter 2010 financial results after the market closes on August 10, 2010. Company management will host a conference call and simultaneous webcast with slide presentation at 1:30 p.m. PT/4:30 p.m. ET, followed by a question and answer session.

Today, EnergyConnect Group, Inc. (ECNG) closed at $0.1690, up 2.42%, on 244,544 volume with 38 trades. The stock’s average daily volume over the past 60 days is 84,710 with a 52-week low/high of $0.04/$0.20.

WebSafety, Inc. (WBSI)

Stock Market News Alert, OTC Stock Exchange, and Whisper from Wall Street reported today on WebSafety, Inc. (WBSI), and we highlight the Company, here at the QualityStocks Daily Newsletter.

WebSafety, Inc. is the leading provider of mobile and computer software solutions. These solutions help to prevent incidences of distracted driving and explicit or degrading texting. They also help to prevent unlawful Internet behavior including cyber predators and cyber-bullying. WebSafety, Inc. trades on the OTC Bulletin Board. The Company has their headquarters in Irving, Texas.

WebSafety, Inc. is the creator of the 'National Wireless Highway Safety Network,' which is driven to save lives. The Company's two main software products are CellSafety and WebSafetyPC. CellSafety disables the texting function while a vehicle is moving. It will monitor and notify of excessive speed and the location of a phone. It monitors texting and cyber-bullying by reviewing vulgar or derogatory words or phrases that are either received or sent from the cell phone and blocks pornography.

In addition, no texting zones may be created that prohibit texting at a location such as school. CellSafety works on all four of the major wireless carriers and on the Blackberry, Android and Nokia operating systems. The CellSafety application is currently available to enterprise, public sector, and government employers. There is a consumer version of the system as well. It features added functionality and controls in order to prevent potentially dangerous activities such as cyber-bullying, scholastic cheating and speeding.

WebSafetyPC monitors and notifies of activities on a PC or laptop. It does so by sending a message of an occurrence of a cyber predator contact, texting and cyber-bullying, and it also blocks pornography.

On July 21, 2010, Manage Mobility, a national management and logistics firm for wireless services, announced a new partnership agreement with WebSafety, Inc. This agreement is to utilize the Company's CellSafety mobile application, which disables texting and emailing in a moving vehicle in order for Manage Mobility’s enterprise, public sector, and government clients to increase their employee safety and significantly reduce operational liability. Manage Mobility is a national management and logistics firm providing fully customized wireless solutions.

WebSafety, Inc. (WBSI) closed Monday's trading session at $2.00, up 25.00%, on 37,405 volume with 62 trades. The stock’s average daily volume over the past 60 days is 516 with a 52-week low/high of $0.90/$1.95.


Greenbackers, Stocks Gone Wild, Thestockwizards.net, and Stock Traders Chat reported earlier on POZEN, Inc. (POZN), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 1996, POZEN, Inc. engages in the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. The Company has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Trading on the NASDAQ Global Market, POZEN, Inc. has their headquarters in Chapel Hill, North Carolina.

The Company has a collaboration agreement with GlaxoSmithKline. This is for Treximet, which is for the acute treatment of migraine attacks with or without aura in adults. They also have a collaboration and license agreement with AstraZeneca for VIMOVO. This is a proprietary fixed dose combination of the proton-pump inhibitor esomeprazole magnesium with the naproxen in a single tablet. It is for the management of pain and inflammation associated with conditions, such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug-associated gastric ulcers.

POZEN, Inc. also develops PA32540, a Phase III clinical trial product. This is a combination of a proton pump inhibitor and aspirin for the secondary prevention of cardiovascular disease in patients at risk for gastric ulcers.

The U.S. Food and Drug Administration (FDA) recently approved the Company's arthritis treatment VIMOVO. POZEN received a $20 million milestone payment from their marketing partner on the drug, AstraZeneca, with this FDA approval. AstraZeneca will pay the Company an additional $25 million milestone payment, should VIMOVO receive approval in another region of the world.

VIMOVO is POZEN Inc.'s second FDA-approved product. Migraine drug Treximet, marketed by GlaxoSmithKline, received approval in 2008.

POZEN announced last week that Elizabeth A. Cermak, their Executive Vice President and Chief Commercial Officer, will present at the BMO Capital Markets Focus on Healthcare Conference on Thursday, August 5, 2010 at 1:45 p.m. (ET), at the Sheraton New York Hotel and Towers. Ms. Cermak’s presentation will be webcast and archived on POZEN’s home page at www.pozen.com. The Company also plans to release second quarter 2010 results on August 3, 2010, before the market opens.

POZEN, Inc. (POZN) closed Monday's session at $7.89, up 5.06%, on 201,148 volume with 1,328 trades. The stock’s average daily volume over the past 60 days is 763,188 with a 52-week low/high of $5.16/$12.68.

The QualityStocks Company Corner

NetSol Technologies, Inc. (NTWK)

The QualityStocks Daily Newsletter would like to spotlight NetSol Technologies, Inc. (NTWK). Today, NetSol Technologies, Inc. closed trading at $0.8445, up 6.90%, on 289,445 volume with 387 trades. The stock’s average daily volume over the past 60 days is 178,621 with a 52-week low/high of $0.70/$1.31.

NetSol Technologies, Inc. announced that the Company was awarded a major software and IT services contract valued at over $1 million with a major U.S. automotive manufacturer's captive finance arm in China.

NetSol Technologies, Inc. (NTWK) a worldwide provider of global business services and enterprise application solutions, leverages its BestShoring(TM) practices and highly experienced resources to deliver high-quality, cost-effective solutions. The ir suite of products and services include credit and finance portfolio management systems, hospital/healthcare information management systems (HIMS), SAP consulting and services, custom development, systems integration, and technical services.

NetSol’s commitment to quality is demonstrated by its achievement of the ISO 9001, ISO 27001, and SEI (Software Engineering Institute) CMMI (Capability Maturity Model) Maturity Level 5 assessments, a distinction shared by less than 100 companies worldwide. These distinctions are a result of adhering to rigorous quality standards, resulting in the delivery of solutions that are secure, reliable, properly planned, and meticulously executed.

Serving the global financial, healthcare, insurance, energy, and technology markets, NetSol has operations, offices, and joint ventures in Adelaide, Bangkok, Beijing, Lahore, London, Riyadh, San Francisco, and San Pedro Sula. NetSol Technologies' clients include Fortune 500 manufacturers, global automakers, financial institutions, utilities, technology providers, and government agencies.

NetSol Technologies, Inc. (NTWK), is well positioned with its core product offerings as it continues to expand into new international market opportunities. Looking forward, the company is very optimistic of its short-term and long-term outlook as it sees strong growth in Asia Pacific as well as the South East Asian markets, while also envisioning unlimited potential for its niche solutions and services in the Americas. Disclaimer

NetSol Technologies, Inc. Blog

NetSol Technologies, Inc. News:

CRWE Wallstreet Announces Stock Watch on SSHO, ENOC, ASTM, NTWK

NetSol North America Sales Rebound After Stream of New Orders From Existing Clients

NetSol Announces the Successful Implementation of NFS Solution by Minsheng Financial Leasing Co., Ltd.

Cellceutix Corp. (CTIX)

The QualityStocks Daily Newsletter would like to spotlight would like to spotlight Cellceutix Corp. (CTIX). Today, Cellceutix Corp. closed trading at $0.62, down 11.43%, on 2,340 volume with 6 trades. The stock’s average daily volume over the past 60 days is 3,241 with a 52-week low/high of $0.23/$1.01.

Cellceutix Corporation (CTIX) announced that they selected Destum Partners to assist in finding a development partner for their psoriasis compound, KM-133.

Cellceutix Corporation (CTIX) an emerging bio-pharmaceutical company, is in the early stages of receiving an influx of media attention and widespread notoriety within the pharmaceutical industry due to the promising results shown during the early development of a compound for the treatment of autism, KM-391, and the approaching Phase 1 clinical trials of Kevetrin™, the company's compound for the treatment of drug-resistant cancers. In addition to these two, Cellceutix currently manages a portfolio of six other promising compounds.

KM-391, a 100% novel compound, is revolutionary in that it addresses the core issues of autism, unlike the pharmaceuticals presently on the market which merely treat the symptoms that result from autism. Preliminary testing of KM-391 revealed that test animals showed a significant increase in serotonin uptake compared to controls with noticeable and measurable positive therapeutic changes. Cellceutix is rapidly developing KM-391 in response to the public outcries received by the company since the results of early testing had been made publicly available.

Kevetrin, Cellceutix's flagship product, is nearing Phase 1 clinical trials on humans with FDA regulated pre-clinical testing completed and the data being properly compiled for the IND application. While most cancer treatments today are derivatives of other compounds, Kevetrin is completely unique. Multidrug resistance, the principal mechanism by which strains of cancer develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy today and represents a huge need for novel cancer treatments.

Kevetrin has been extensively studied in animal models of lung, breast, and colon cancers, targeting carcinoma strains that have proven resistant to standard therapies available on the market today with the results showing greater tumor growth delay than present therapies and strong efficacy in mouse models with increasing dosages. A successful drug for the treatment of drug-resistant cancers is purported to generate billions of dollars in annual revenues.

The Company has procured leading figures in the health and science arenas to lead its development efforts. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as those who have been integral to mergers, acquisitions and the generation of exorbitant revenues through ground breaking therapies while holding high-level executive and research positions at industry giants such as Pfizer and Eli Lilly. Holding over a century of highly relevant experience in the pharmaceuticals industry, the team has been assembled with the specific goal of duplicating these past successes while revolutionizing much needed treatments for today's most challenging diseases. Disclaimer

Cellceutix Corp. Blog

Cellceutix Corp. News:

Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to Filing Investigational New Drug (IND) Application

AllPennyStocks.com News: Drug-Resistant Cancers Now a Focal Point for Progressive Biotechs

AllPennyStocks.com Announces Corporate Write-Up on Cellceutix Corp. (OTCBB:CTIX)

Simulated Environment Concepts, Inc. (SMEV)

The QualityStocks Daily Newsletter would like to spotlight Simulated Environment Concepts, Inc. (SMEV). Today, Simulated Environment Concepts, Inc. closed trading at $0.0126, up 40.00%, on 69,000 volume with 6 trades. The stock’s average daily volume over the past 60 days is 136,421 with a 52-week low/high of $0.001/$0.07.

Simulated Environment Concepts, Inc. (SMEV) is focused on manufacturing and distributing their patented SpaCapsule® as well as continued innovation in the areas of anti-aging, cosmetics, relaxation, cellulite reduction, and weight loss. Finding use in numerous environments such as relaxation centers, golf clubs, ski lounges, gyms, and health clubs, the SpaCapsule® provides next generation de-stressing and relaxation.

The company’s founders, Dr. Ella Frenkel and Dr. Ilya Spivak, initially capitalized Simulated Environment Concepts Inc. with several million dollars of their own money. With this initial investment, the company worked on, and succeeded in developing, the sleek and stylish looking pressurized dry water massage relaxation station.

SpaCapsule® is a full body massage, aromatherapy, audio and video entertainment system. The capsules are fused with advanced modern technology and healing methods of aromatherapy and audiovisual relaxation techniques, incorporating proprietary water-jet and pressure-jet technology that requires no on-site plumbing. Weighing approximately 500 lbs, the capsule only requires standard electric service.

Simulated Environment Concepts, Inc. (SMEV) anticipates progressive and consistent growth over the next six years. With individuals spending billions of dollars on de-stressing, weight loss, anti aging, cosmetics, massage and physical rehabilitations, the company is in a position to experience explosive growth from current levels. Disclaimer

Simulated Environment Concepts, Inc. Blog

Simulated Environment Concepts, Inc. News:

Simulated Environment Concepts Continues Global Expansion With Another Multi-Million Dollar International Production Deal by Way of United Arab Emirates' Distributor ;

Dermscan's Research to Support SpaCapsule's Weight Loss/Anti-Cellulite Benefits

Simulated Environment Concepts Receives Additional Operation Capital

Uranium Energy Corp. (UEC)

The QualityStocks Daily Newsletter would like to spotlight Uranium Energy Corp. (UEC) Today, Uranium Energy Corp. closed trading at $2.65, up 8.16%, on 803,808 volume with 2,489 trades. The stock’s average daily volume over the past 60 days is 360,458 with a 52-week low/high of $2.10/$4.16.

Uranium Energy Corp. (UEC) is a U.S.-based exploration and development company focused on near-term uranium production in the U.S. The company’s operations are managed by professionals who have earned a reputable profile through many decades of hands-on experience in the key facets of uranium exploration, development and mining.

Uranium Energy controls one of the largest databases of historic uranium exploration and development in the nation. Using this knowledge base, the company has acquired and is advancing exploration properties of merit throughout the southwestern U.S., a region known as being the most concentrated area for uranium mining in the United States.

The Company’s fully licensed and permitted Hobson processing facility is central to all of its projects in South Texas. Well financed to execute on its key programs, Uranium Energy's Palangana is-situ recovery project is fully permitted, and its Goliad in-situ recovery project is in the final stages of mine permitting for production.

The company’s strategy of acquiring exploration databases and leveraging those databases to generate acquisition targets has proven to be effective thus far. With plans to continue aggressively pursuing this strategy, Uranium Energy Corp is well positioned to capitalize on the world’s first significant alternative energy boom. Disclaimer

Uranium Energy Corp. Blog

Uranium Energy Corp. News:

Uranium Energy Corp Announces Results of AGM

Uranium Energy Corp Announces Historical Resource of 1.5 Million Pounds eU3O8 at the Company's Salvo Project in South Texas

BUYINS.NET Updates Uranium Energy Corp SqueezeTrigger Report

Micro Identification Technologies, Inc. (MMTC) Ramping Up

Micro Identification Technologies Inc., developer of the revolutionary MIT 1000 patented microbial ID system, is targeting a rapidly growing market resulting from increased demands in the areas of food safety, general health, and homeland security. The company has already produced the system for a number of high-end organizations, including the U.S. Department of Agriculture, the Japanese Ministry of Food Safety, and even a university in Malaysia, and recently announced the initiation of an internal expansion program. The expansion is made possible by a manufacturing contract with OSI Optoelectronics to produce the systems, and an equity placement agreement from the private equity firm of Dutchess Capital.

The MIT 1000 represents a new paradigm in the critical detection of pathological microbes that kill countless people worldwide every year. The system intelligently leverages advanced software to read the patterns generated by reflected laser light illuminating the bacteria, and can quickly identify various pathogens without the need of expensive laboratory intervention.

MIT’s Chairman, Michael Brennan, spoke of the progress made. “The MIT 1000 is patented, independently tested and is a certified test method for food safety. More importantly, it can annually save thousands of lives and tens of millions in healthcare costs by the rapid identification of pathogenic bacteria and other microbes. We are on track with this year’s goal to begin quantity deliveries in 4Q 2010, but need to increase our system support and microbiological research capabilities in conjunction with supporting the food industry’s obvious safety requirements.”

Emergence of the new technology has occurred at a time when concerns about food safety have significantly increased, and with the government approving the first major changes to food safety laws in 70 years. The Washington Post reported, “These actions follow a wave of food-borne illnesses over the past three years, involving products as varied as spinach, peanuts, cookie dough and meat, which has shaken consumer confidence and made the issue a priority for congressional leaders and the White House. Food illnesses sicken one in four Americans and kill 5,000 each year, according to government statistics. Tainted food has cost the food industry billions of dollars in recalls, lost sales and legal expenses. Under the legislation, the FDA will get new enforcement powers and be able to impose beefed-up civil and criminal penalties. One provision allows the FDA to declare food ‘adulterated’ simply if the grower or manufacturer has failed to follow safety standards, regardless of whether the food is actually tainted.”

Revenues for all rapid testing methods total over $5 billion annually, with food safety totaling over $3 billion.

Strength of Cellceutix, Inc. (CTIX) Pipeline Results in Contracting of Destum Partners to Partner Psoriasis Compound

Cellceutix Corporation announced this morning that they have contracted acclaimed consulting firm, Destum Partners, to aggressively seek a partner to develop their compound, KM-133, for the treatment of psoriasis. Destum has a distinguished history of establishing partnerships in the biotechnology industry to meet the developmental needs for promising compounds.

Cellceutix has been receiving notoriety recently with a series of press releases regarding Kevetrin, their compound in development for multi-drug resistant cancers, and KM-391, their compound for the treatment of the core issues of autism. Kevetrin is approaching Phase I human trials and has displayed extremely promising results in pre-clinical studies. As a result, major pharma and financial institutions have recently contacted Cellceutix to learn more about the Company and the promising cancer compound that it possesses. In the area of autism research, Cellceutix stands amongst the top of industry leaders, big and small, as they have already conducted several pre-clinical studies on KM-391 with very promising data being compiled.

Interestingly, and also akin to the overall Cellceutix business philosophy, Cellceutix has maintained a very “low-key” approach to the development of their compound for psoriasis. While many small biotechs would be publishing news regularly on a compound of this nature and potential, the Cellceutix management team has been carefully deliberating over the most effective way to continue the development of KM-133 to support shareholder value and financial responsibility of the Cellceutix budget.

In a conversation with Leo Ehrlich, Chief Financial Officer of Cellceutix, we questioned what other options were available for the development of KM-133. Mr. Ehrlich explained that not only could Cellceutix develop the compound on their own, but that they had recently been contacted by officials from the Vietnamese government. The Vietnamese see extremely promising potential in KM-133 and as they wish to establish themselves as a world-leader in the area of medical tourism, they see value in the development of KM-133 in their country as a possible opportunity to launch this initiative. The Cellceutix management spent many hours in discussions about all avenues and decided that partnering for the development was the best course of action for its shareholders.

In a video that can be viewed on the Cellceutix website at www.cellceutix.com, CEO George Evans states that, “it is really an embarrassment of riches” as the Company knows the potential of KM-133, yet is focused heavily on the development of Kevetrin and KM-391. In the press release this morning, Mr. Evans explains, “This decision is ultimately a consequence of the strength of our pipeline.” He continued, “With our primary focus on the impending IND filing for Kevetrin™ and our work on KM-391 for autism, our board determined that this approach is the best way to increase value for our shareholders. We selected Destum because of their deep experience in the dermatology space and their excellent recent track record in concluding development deals.”

The data from results of testing already completed for KM-133 has been extremely promising. In a human xenograft animal model of psoriasis, KM-133 reduced psoriasis significantly more than controls. Psoriasis did not recur with KM-133 during the entire 180 day course of the experiment, whereas psoriasis reoccurred in the groups treated with methotrexate, a drug commonly used for the treatment of severe psoriasis, after an average of 61 days. The effectiveness demonstrated by KM-133 in these studies, if confirmed in human trials, would position the compound in a very large market.

According to a report published by Research and Markets, the psoriasis market for the seven major markets in 2008 was $2.5 billion and is projected to grow at a compound annual growth rate of 3.4% through 2018. According to the National Institutes of Health (NIH), as many as 7.5 million Americans (125 million worldwide) have psoriasis making it one of the most prevalent autoimmune diseases in the U.S. affecting all ages of both sexes.

In addition, KM-133 may be eligible for an abridged FDA approval process that would allow the compound to go directly into human trials. The rule, 505(b)(2), permits compounds with an active ingredient that has previously been approved by the Food and Drug Administration to forego pre-clinical testing. Knowing that this rule has saved companies millions of dollars and significant time, Cellceutix believes that this fact, coupled with the promising data already compiled, will make KM-133 very appealing for development with a partnering company.

Gareth Lugg, Managing Director and Co-Founder of Destum Partners commented, “We are very pleased that Cellceutix selected us for this project. Although Cellceutix is a small company, the strength of their compounds in development is extraordinary.” Mr. Lugg continued, “Our extensive experience in the dermatological industry has us very bullish on the partnership potential for this compound.”

Destum Partners has extensive advisory experience both in the dermatology and autoimmune therapeutic areas. They have worked with companies such as Collagenex and Pfizer specifically focused on dermatology. Most recently, Destum Partners completed a partnering agreement on behalf of Diamyd Medical AB with OMJPI a division of Johnson and Johnson for the treatment and prevention of Type I Diabetes — an autoimmune disease. Diamyd received an upfront payment of US $45 million, and has the potential to receive US $580 million in milestone payments.

Once again, this “under the radar” company has brought significant news to the table about another one of the eight compounds in their portfolio. More information about Cellceutix, their compounds and the investment opportunity that they possess can be found on their corporate website at www.cellceutix.com.

NetSol Technologies, Inc. (NTWK) Inks Contract to Implement NFS CAP Solution with a Major U.S. Auto Manufacturer in China

NetSol Technologies, Inc., a worldwide provider of global IT and enterprise application solutions, announced this morning that it was awarded a major software and IT services contract valued more than $1 million with a major U.S. automotive manufacturer’s captive finance arm in China. According to the press release, NetSol will provide its Credit Application Processing solution to fully automate point of sale (POS) functions in the client’s Chinese dealer network as well as install its next-generation platform to capture all credit and client data at the point of sale to streamline and automate the entire credit application capture process.

Naeem Ghauri, President and Head of Global Sales at NetSol, stated, “This is a major win for NetSol’s China operations. Our state-of-the-art auto leasing platform has become the de facto gold standard in the Chinese IT market. This new win clearly establishes NFS as a market leader with over 90% IT market share in China’s captive auto finance sector. We expect to sign a number of new deals in the foreseeable future, as our pipeline remains strong and growing.”

China overtook the U.S. last year to become the world’s largest auto market, with more than 13 million vehicles sold during the year. Research firm J.D. Power and Associates has estimated that sales of passenger vehicles (a category that includes passenger cars, SUVs and minivans) in China will increase from 8.7 million vehicles in 2009 to 13.5 million vehicles by 2015, a 55.2% increase.

Credit Application Processing (CAP), a component of the NetSol Financial Suite (NFSTM) of products, is a web-based credit evaluation system that provides finance and leasing companies with the ability to quickly assess the merit and risk level of an applicant applying for a loan or a lease. Although the system is designed to seamlessly integrate with NetSol’s POS module, it can also be customized to link to any third-party point of sale system.

Northwest Bancshares, Inc. (NWBI) Reports Higher Second Quarter Earnings for 2010

Northwest Bancshares, Inc. reported a doubling of net income in the second quarter of 2010 over the same quarter last year. The company earned net income of $16.1 million, or $0.15 per diluted share, in the quarter ending 6/30/2010, compared to net income of $7.3 million, or $0.07 per diluted share, in the corresponding quarter of 2009.

Northwest Bancshares, Inc. also increased net income sequentially from the quarter ending 3/31/2010, when the company earned net income of $13.2 million, or $0.12 per diluted share.
The management of Northwest Bancshares, Inc. reported growth in loans and deposits in the second quarter of 2010, and the company successfully utilized the capital that the company raised late in 2009.

William J. Wagner, the CEO of Northwest Bancshares, Inc., said, “Our most recent quarter was one of significant achievement for Northwest Bancshares, Inc. Our earnings increased significantly over both the previous quarter and the prior year and we had great success in growing both our loan portfolio and our deposits. We continue to make progress deploying the proceeds of our December 2009 stock offering and, to date in 2010, we have moved $246 million from short-term investments to loans.”

Northwest Bancshares, Inc. is a bank holding company that owns Northwest Savings Bank and Northwest Consumer Discount Company. Northwest Savings Bank has 171 branches in five states: Florida, Maryland, New York, Ohio and Pennsylvania. Northwest Consumer Discount Company is a consumer finance company with fifty-two offices in Pennsylvania.


Sponsors of the Day


The QualityStocks Public Company Sponsor News

Micro Identification Technologies Inc. (MIT) (MMTC) MIT Initiates Expansion Plans Enabled by Recently Completed Manufacturing and Financing Agreements



About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336